7794 results for "canc*"

in 9.14 milliseconds.

• RAIDs Whole Exome Sequencing dataset

  Here, we describe molecular alterations in 291 cervical cancer patients using 291 paired tumor and constitutional frozen samples sequenced using Whole Exome Sequencing technology. Tumor samples were obtained from cervical tumor tissue collected at diagnosis. FASTQ files are deposited files are deposited in the dataset

  Dataset EGAD50000001480

• RAIDs shallow Whole Genome Sequencing dataset

  shallow Whole Genome sequencing of 302 patients with cervival cancer. Tissue cervical cancer at diagnosis....

  Dataset EGAD50000001481

• Colorectal Cancer, NDS Oxford

  Data Access Committee governing the terms on which access will be granted to the genotype data generated within the Colorectal Cancer studies research group at the Nuffield Department of Surgical Sciences (NDS), University of Oxford.

  Dac EGAC50000001075

• Mutational order shapes cell state and chromatin accessibility during early colorectal cancer evolution

  Using CRISPR mediated gene editing in patient-derived human colon organoids, we investigate how mutational order shapes cell state and downstream phenotype. We find that loss of FBXW7 on a wild-type background produces minimal phenotypic or transcriptomic change but induces a subtle shift towards a foetal-like, regenerative stem cell identity. Strikingly, the order of mutation acquisition produces markedly different outcomes. 'FA' organoids (i.e. FBXW7 loss preceding APC mutation) retain a near-normal morphology and transcriptional profile. In contrast, 'AF' organoids adopt a proliferative stem cell state and a more transformed phenotype, despite identical final genotype. These differences were associated with distinct chromatin accessibility landscapes, and reflect a cell state-dependent constraint on the transcriptional consequences of subsequent mutations.

  Study EGAS50000001945

• RNA-seq of Breast Cancer Cells in Bone-Mimetic Matrices

  Bulk RNA sequencing dataset of four breast cancer cell lines (MDA-MB-231, SCP2, MCF7 and BT-4747) cultured in collagen or in collagen-hydroxyapatite (bone mimetic) matrices to model microenvironment-driven gene expression changes.

  Study EGAS50000001966

• RNA sequencing of breast cancer cells in collagen and mineralized matrices

  The dataset includes 45 FASTQ files generated from RNA sequencing (RNA-seq) of breast cancer cells cultured in monolayer, 3D collagen and 3D mineralized extracellular matrices. RNA-seq libraries were prepared using the Illumina Stranded Total RNA Prep with Ribo-Zero Plus (Illumina). Sequencing was performed on Illumina NextSeq 550 System using NextSeq 500/550 High-Output v2.5 Kit - 150 cycles (Illumina)

  Dataset EGAD50000002847

• MD Anderson Data Access Committee: Pembrolizumab in Advanced Rare Cancers

  Dac EGAC50000000860

• Immune-driven response to chemoradiotherapy in POLE-mutated rectal cancer

  This study aimed to investigate the chemoradiotherapy response and potential molecular mechanisms underlying chemoradiotherapy response in POLE exonuclease domain mutation-positive rectal cancer.

  Study JGAS000919

• Research on constructing a genome analysis database for malignant tumors

  Germline pathogenic variants (GPVs) in BRCA1/2 are established cancer predisposition factors; however, their biological and clinical significance in gastric cancer (GC) remain unclear. In particular, the directionality and evolutionary timing of locus-specific loss of heterozygosity (LOH) and their relationships with homologous recombination deficiency (HRD) have not been systematically examined in BRCA1/2-associated GC. We conducted integrative genomic analyses of four GCs from BRCA1/2 GPV carriers using tumour-normal tissue paired whole-exome sequencing and allele-specific copy number profiling. LOH directionality was inferred by integrating the variant allele fraction, tumour purity, and locus-specific copy number. The relative timing of LOH events during tumour evolution was estimated, and HRD was evaluated using genome instability scores and mutational signature analyses.

  Study JGAS000920

• Malignancy of breast cancer cells is increased in a luminal-hybrid state defined by progenitor markers CD146 and keratin 14

  We first analyzed a patient-derived xenograft (PDX)-derived breast cancer cell line by dividing cell populations based on CD146-expression by FACS and found that this marker defines a cellular state with increased expression of a selection of luminal hybrid markers, including KRT14. We then knocked out CD146 or KRT14 in another patient-derived xenograft (PDX)-derived breast cancer cell line to investigate further the role of these markers in the hybrid state. For all these populations, we studied their gene expression by bulk RNA sequencing.

  Study EGAS50000001972